Your browser doesn't support javascript.
loading
Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report.
Shimizu, Nobuaki; Hasumi, Masaru; Muramatsu, Kazumichi; Tsuji, Yusuke; Takaku, Youtarou.
Afiliação
  • Shimizu N; Department of Urology, Gunma Cancer Center, Ota, Japan.
  • Hasumi M; Department of Urology, Gunma Cancer Center, Ota, Japan.
  • Muramatsu K; Department of Urology, Gunma Cancer Center, Ota, Japan.
  • Tsuji Y; Department of Urology, Gunma Cancer Center, Ota, Japan.
  • Takaku Y; Department of Urology, Shibukawa Medical Center, Shibukawa, Japan.
Urol Case Rep ; 39: 101843, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34540590
Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the abnormal accumulation of surfactant-derived substances in the lungs. To the best of our knowledge, the successful treatment of metastatic renal cell carcinoma in patients with PAP has not been reported. Here, we describe such treatment of a patient via avelumab plus axitinib therapy. After four courses of treatment, computed tomography showed size reduction of the pulmonary metastatic nodule and improvement of PAP. This study highlights that avelumab plus axitinib therapy is a safe and effective treatment option for metastatic renal cell carcinoma, even in patients with PAP.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Urol Case Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Urol Case Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão